Dimension Therapeutics

Dimension Therapeutics — Merger or Acquisition (August 2017)

35 slides from Dimension Therapeutics's merger presentation, Aug 25, 2017

  1. Slide 1: Corporate Presentation August 25, 2017

    Corporate Presentation August 25, 2017 Exhibit 99.3

  2. Slide 2: Forward-looking statements

    Forward-looking statements This presentation includes “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements express a belief, expectation or intention and are gen

  3. Slide 3: REGENXBIO: seeking to improve lives through the curative potential of gene therapy

    REGENXBIO: seeking to improve lives through the curative potential of gene therapy Proprietary NAV® Technology Platform includes exclusive worldwide rights to over 100 AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 Expect to provide interim trial updates on RGX-314 (wet AMD) and RGX-501 (HoFH)

  4. Slide 4: REGENXBIO acquisition of Dimension Therapeutics

    REGENXBIO acquisition of Dimension Therapeutics Further bolsters RGNX industry-leading clinical-stage pipeline 1 Based on RGNX share price as of market close on August 24, 2017 All-stock transaction at an exchange ratio of 0.1573 RGNX shares for each Dimension share, an implied offer of $3.41 per sh

  5. Slide 5: Dimension pipeline

    Dimension pipeline Complementary addition to RGNX existing metabolic disease franchise

  6. Slide 6: Overview of Dimension two lead product candidates

    Overview of Dimension two lead product candidates OTC Deficiency Vector Gene ROA Special Status AAV8 OTC Intravenous Orphan Drug Designation Vector Gene ROA Special Status AAV8 G6PC Intravenous Orphan Drug Designation GSD1a

  7. Slide 7: Over 20 partnered programs being developed by nine NAV Technology Licensees

    Indication Licensee Hemophilia A GSDIa ALS SOD1 Rett Syndrome Undisclosed MPS IIIA CPVT Indication Licensee Hemophilia A OTC Deficiency Crigler-Najjar A1AT Deficiency SMA MPS IIIA XLMTM Pompe Disease Indication Licensee Citrullinemia Type I PKU Wilson Disease Achromatopsia Choroideremia Parkinson’s

  8. Slide 8: REGENXBIO's lead programs

    REGENXBIO’s lead programs Retinal Diseases Metabolic Diseases Neurodegenerative Diseases Indication Development Stage Anticipated Research Preclinical Clinical Milestones Mucopolysaccharidosis Type I (MPS I) Mucopolysaccharidosis Type II (MPS II) RGX–111 RGX–121 Interim trial update late 2017 Wet ag

  9. Slide 9: Internal Development Programs

    Internal Development Programs

  10. Slide 10: RGX-314 for treatment of wet age-related macular degeneration

    RGX–314 for treatment of wet age-related macular degeneration (wet AMD) Blurring of central vision and progressive vision loss due to formation of leaky blood vessels in the eye VEGF inhibitors can prevent / reverse new blood vessel formation Frequency / uncomfortable administration of current anti-

  11. Slide 11: RGX-314 potential for long-term therapeutic anti-VEGF expression

    RGX–314 – potential for long-term therapeutic anti-VEGF expression Improved AAV vector technology Potentially eliminate frequent, uncomfortable administration of current anti-VEGF therapies that affect compliance, and ultimately efficacy Current standard of care includes FDA-approved mAbs and mAb fr

  12. Slide 12: RGX-314 expression in non-human primates

    Sponsor Vector ROA Transgene Dose (GC/eye) Max. expression (ng/ml)2 AAV8 Subretinal anti-VEGF fab 1.0e11 4,992 AAV2 Subretinal sFlt 8.0e11 0.217 AAV2 Intravitreal sFLT01 2.4e10 528 RGX–314 has significant potential advantages over earlier generation candidates for wet AMD gene therapy RGX–314 expres

  13. Slide 13: RGX-314 Phase I clinical trial in wet AMD

    RGX–314 Phase I clinical trial in wet AMD Objectives Key inclusion criteria Male or female ≥ 50 years of age Wet AMD patients requiring frequent anti-VEGF therapy, with a documented history of response Documented response to anti-VEGF at trial entry (assessed by SD–OCT at week 1) Vision of 20/100 to

  14. Slide 14: RGX-314 Phase I clinical trial administration and dose escalation

    RGX–314 Phase I clinical trial – administration and dose escalation Expected dose escalation pathway Dose 1 n = 6 Safety review1 Dose 2 n = 6 Dose 3 n = 6 3x109 gc/eye Safety review1 1x1010 gc/eye 6x1010 gc/eye anti–VEGF injection Administration and follow-up timeline Baseline assessment Follow up T

  15. Slide 15: RGX-501 for treatment of homozygous familial hypercholesterolemia (HoFH)

    RGX–501 for treatment of homozygous familial hypercholesterolemia (HoFH) Defective LDLR gene leads to limited / no LDL cholesterol receptors, allowing LDL to build up in bloodstream Total cholesterol levels >500 mg/dL Coronary artery disease at young age Even with existing standard of care therapies

  16. Slide 16: Preclinical studies in familial hypercholesterolemia mice

    Familial hypercholesterolemia mice injected with AAV8 Mouse LDLR gene or control Preclinical studies using NAV Gene Therapy have shown a significant improvement in familial hypercholesterolemia mice Stable correction of cholesterol levels seen for nearly one year 0 100 200 300 400 500 600 700 800 7

  17. Slide 17: RGX-501 Phase I/II clinical trial in HoFH

    RGX–501 Phase I/II clinical trial in HoFH Objectives Key inclusion criteria Male or female ≥ 18 years of age Untreated and/or treated LDL-C levels and clinical presentation consistent with the diagnosis of HoFH Molecularly defined LDLR mutations at both LDLR alleles Stable concurrent allowed lipid l

  18. Slide 18: RGX-501 Phase I/II trial administration and dose escalation

    RGX–501 Phase I/II clinical trial – administration and dose escalation Expected dose escalation pathway Dose 1 n = 3 Safety review1 Dose 2 n = 3 Dose 2 n = up to 6 2.5x1012 gc/kg Safety review1 7.5x1012 gc/kg 7.5x1012 gc/kg Screening stage Follow up Treatment evaluation 0 4 8 26 12 Weeks 52 Secondar

  19. Slide 19: RGX-111 for treatment of mucopolysaccharidosis Type I (MPS I)

    RGX–111 for treatment of mucopolysaccharidosis Type I (MPS I) Defective IDUA gene leads to reduced ability to process glycosaminoglycans (GAGs), a cellular waste product Severe GAG buildup causes neurodegeneration and early death Available treatment is inadequate to treat neurodegeneration; bone mar

  20. Slide 20: Preclinical studies show improvement in MPS I cats

    Preclinical studies using NAV Gene Therapy have shown a significant improvement in MPS I cats IDUA Expression in Cats Following AAV9 Delivery Substantially greater CNS correction than that observed in MPS I cats treated with BMT at similar ages, with histological correction throughout the CNS 0 50 1

  21. Slide 21: RGX-111 Phase I clinical trial in MPS I

    RGX–111 Phase I clinical trial in MPS I Objectives Key inclusion criteria Male or female First patient ≥18 years of age Subsequent patients ≥6 years of age Documented evidence of early-stage neurocognitive deficit due to MPS I A score of ≥1 standard deviation below mean on intelligent quotient testi

  22. Slide 22: RGX-111 Phase I trial administration and dose escalation

    RGX–111 Phase I clinical trial – administration and dose escalation Expected dose escalation pathway Dose 11 n = 2 Safety review2 Dose 2 n = 3 2.0x109 gc/g brain mass 1.0x1010 gc/g brain mass Screening stage Follow up Treatment evaluation 0 4 8 24 Weeks 52 Safety endpoint Administration and follow-u

  23. Slide 23: RGX-121 for treatment of mucopolysaccharidosis Type II (MPS II)

    RGX–121 for treatment of mucopolysaccharidosis Type II (MPS II) Defective IDS gene leads to reduced ability to process GAGs Severe GAG buildup causes neurodegeneration and early death (similar phenotype to severe MPS I) X-linked recessive disease (predominantly occurs in males) Available treatment i

  24. Slide 24: Preclinical studies show improvement in MPS II mice

    Preclinical studies using NAV Gene Therapy have shown a significant improvement in MPS II mice Reduction in Storage Lesions Following AAV9 Delivery Statistically significant reduction in storage lesions at all dose levels Source: Hinderer et al. 2016 Human Gene Therapy

  25. Slide 25: A single transduced cell has potential to correct many other cells

    A single transduced cell has potential to correct many other cells Cross–correction is a key treatment advantage in MPS diseases Protein secreted by transduced cells NAV Vector delivers healthy gene to cells RNA Gene NAV Vector Protein taken up by non-transduced cells 1 2 3 Protein

  26. Slide 26: NAV Technology Platform

    #6} REGENXBIO NAV® Technology Platform

  27. Slide 27: NAV Technology Platform is based on a broad and deep IP portfolio

    Exclusive rights to more than 100 patents and patent applications worldwide The NAV Technology Platform is based on a broad and deep IP portfolio NAV Vectors … AAV7, AAV8, AAV9, AAVrh10 Over 100 other novel AAV sequences Sequences that are at least 95% identical to these capsids

  28. Slide 28: Key features of REGENXBIO's NAV Technology Platform

    Key features of REGENXBIO’s NAV Technology Platform Higher gene expression Longer-term gene expression Broad and novel tissue selectivity Lower immune response Improved manufacturability Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B Intravascular AAV9 Preferentially Targets

  29. Slide 29: NAV Vectors higher gene expression than early generation AAV vectors

    NAV Vectors – higher gene expression than early generation AAV vectors AAV2 AAV8 NAV Vector AAV8: 10x–100x greater gene expression AAV2 AAV8 NAV Vector AAV8: More efficient gene delivery to sites of most retinal dystrophies1 Photoreceptors (PR) Retinal Pigment Epithelium (RPE) Photoreceptors (PR) Re

  30. Slide 30: Strength in AAV production and biologics scale up

    Strength in AAV production and deep experience in biologics scale up and commercialization REGENXBIO | cGMP Manufacturing Natural host for AAV Robust process utilizing mammalian cell lines with known regulatory history Core in-house capability in adapting adherent cell lines to suspension cell cultu

  31. Slide 31: Team and Conclusion

    #6} REGENXBIO Team and Conclusion

  32. Slide 32: The REGENXBIO team

    The REGENXBIO team Name Position Prior / Current Affiliations Ken Mills President, CEO & Co-Founder; Director Olivier Danos, Ph.D. Chief Scientific Officer Vit Vasista Chief Financial Officer Stephen Yoo, M.D. Chief Medical Officer Faraz Ali Chief Business Officer Curran Simpson SVP, Technical Opera

  33. Slide 33: Financial results and guidance

    Financial results and guidance Financial highlights Program guidance and anticipated milestones Phase I trial enrollment on-going; interim trial update late 2017 R&D expense: G&A expense: Net loss: $31 $13 $36 2017 financial guidance Expect 2017 cash burn to be between $75 million and $80 million2 B

  34. Slide 34: REGENXBIO: seeking to improve lives through the curative potential of gene therapy

    REGENXBIO: seeking to improve lives through the curative potential of gene therapy Proprietary NAV® Technology Platform includes exclusive worldwide rights to over 100 AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 Expect to provide interim trial updates on RGX-314 (wet AMD) and RGX-501 (HoFH)

  35. Slide 35: Thank You

    gos R=G=NXBIC" Leader in AAV gene therapy Thank You

Dimension Therapeutics — Merger or Acquisition (August 2017) on 6ix